Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

- Dowsett, Mitch, Cuzick, Jack, Coombes, Charles, Snowdon, Claire, Gnant, Michael, Jakesz, Raimund, Kaufmann, Manfred, Boccardo, Francesco, Godwin, Jon, Davies, Christina, Peto, Richard, Ingle, Jim, Coates, Alan, Forbes, John, Bliss, Judith, Buyse, Marc, Baum, Michael, Buzdar, Aman, Colleoni, Marco

Predictive algorithms for adjuvant therapy: transATAC

- Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U., Forbes, John, Pineda, S., Cuzick, Jack

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

- Sestak, Ivana, Singh, Shalini, Eastell, Richard, Cuzick, Jack, Blake, Glen M., Patel, Rajesh, Gossiel, Fatma, Coleman, Rob, Dowsett, Mitch, Forbes, John F., Howell, Anthony

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

- Cuzick, Jack, Sestak, Ivana, Bonanni, Bernardo, Palva, Tina, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Knox, Jill, Cawthorn, Simon, Saunders, Christobel, Roche, Nicola, Mansel, Robert E., von Minckwitz, Gunter

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer

- Sestak, Ivana, Harvie, Michelle, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Cuzick, Jack

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

- Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

- Afentakis, Maria, Dowsett, Mitch, Sestak, Ivana, Salter, Janine, Howell, Tony, Buzdar, Aman, Forbes, John, Cuzick, Jack

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial

- Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

- Sestak, Ivana, Distler, Wolfgang, Forbes, John F., Dowsett, Mitch, Howell, Anthony, Cuzick, Jack

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study

- Dowsett, Mitch, Cuzick, Jack, Howell, Anthony, Bugarini, Roberto, Baehner, Frederick L., Shak, Steven, Wale, Christopher, Forbes, John, Mallon, Elizabeth A., Salter, Janine, Quinn, Emma, Dunbier, Anita, Baum, Michael, Buzdar, Aman

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

- Cuzick, Jack, Sestak, Ivana, Forbes, John F., Dowsett, Mitch, Cawthorn, Simon, Mansel, Robert E., Loibl, Sibylle, Bonanni, Bernardo, Evans, D. Gareth, Howell, Anthony

Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial

- Ring, Alistair, Sestak, Ivana, Baum, Michael, Howell, Anthony, Buzdar, Aman, Dowsett, Mitch, Forbes, John F., Cuzick, Jack

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of randomised controlled trial

- Cuzick, Jack, Sestak, Ivanka, Forbes, John F., Dowsett, Mitch, Cawthorn, Simon, Mansel, Robert E., Loibl, Sibylle, Bonanni, Bernardo, Evans, D. Gareth, Howell, Anthony

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors

- Tang, Gong, Cuzick, Jack, Costantino, Joseph P., Dowsett, Mitch, Forbes, John F., Crager, Michael, Mamounas, Eleftherios P., Shak, Steven, Wolmark, Norman

Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer

- Dowsett, Mitch, Sestak, Ivana, Buus, Richard, Lopez-Knowles, Elena, Mallon, Elizabeth, Howell, Anthony, Forbes, John F., Buzdar, Aman, Cuzick, Jack

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer

- Cuzick, Jack, Dowsett, Mitch, Howell, Anthony, Buzdar, Aman U., Forbes, John F., Pineda, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, Green, Andrew R., Ellis, Ian O.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

- Cuzick, Jack, Sestak, Ivana, Mershon, John, Mitlak, Bruce H., Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D. Lawrence, Bonanni, Bernardo, Costantino, Joseph P., Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F., Ford, Leslie, LaCroix, Andrea Z.